Tyme Technologies Announces Launch of a Pancreatic Research Program with the Mayo Clinic Led by Dr. Martin Fernandez-Zapico

NEW YORK, Dec. 13, 2016, TYMI, (GLOBE NEWSWIRE) Tyme Technologies, Inc. (“Tyme” or “the Company”) (OTCQB:TYMI), a clinical-stage pharmaceutical company focused on developing highly targeted cancer therapeutics for a broad range of oncology indications, today announced the launch of a Pancreatic Research Program with the Mayo Clinic led by Dr. Martin Fernandez-Zapico. Dr. Martin E. Fernandez-Zapico, Associate Professor of Medicine and Pharmacology at the Mayo Clinic, is an international expert in the field of pancreatic cancer, a disease predicted
http://bit.ly/2gyicwZ